Table of Contents_x000D_
List of Tables_x000D_
List of Figures_x000D_
1 Introduction_x000D_
1.1 What Is This Report About?_x000D_
1.2 Hormonal Disorders Market Segmentation_x000D_
1.3 Definitions of Markets Covered in the Report_x000D_
2 Hormonal Disorders Market, United States_x000D_
2.1 Hormonal Disorders Market, United States, Revenue ($m), 2024-2036_x000D_
2.1.1 Thyroid Function Tests Market, United States, Revenue ($m), by Segment, 2024-2036_x000D_
2.2 Hormonal Disorders Market, United States, Volume (Units), 2024-2036_x000D_
2.2.1 Thyroid Function Tests Market, United States, Volume (Units), by Segment, 2024-2036_x000D_
2.3 Hormonal Disorders Market, United States, Average Price ($), 2024-2036_x000D_
2.4 Hormonal Disorders Market, United States, Company Share by Revenue ($m), 2025_x000D_
3 Hormonal Disorders Market Pipeline Products_x000D_
3.1 Hormonal Disorders Market Pipeline Products_x000D_
3.2 Hormonal Disorders – Pipeline Products by Stage of Development_x000D_
3.3 Hormonal Disorders – Pipeline Products by Segment_x000D_
3.4 Hormonal Disorders – Pipeline Products by Territory_x000D_
3.5 Hormonal Disorders – Pipeline Products by Regulatory Path_x000D_
3.6 Hormonal Disorders – Pipeline Products by Estimated Approval Date_x000D_
4 Overview of Key Companies in United States, Hormonal Disorders Market_x000D_
4.1 Siemens Healthineers AG_x000D_
4.1.1 Company Overview_x000D_
4.2 Beckman Coulter Inc_x000D_
4.2.1 Company Overview_x000D_
4.3 Roche Diagnostics International Ltd_x000D_
4.3.1 Company Overview_x000D_
4.4 Abbott Laboratories_x000D_
4.4.1 Company Overview_x000D_
4.5 Ortho Clinical Diagnostics Holdings Ltd (Inactive)_x000D_
4.5.1 Company Overview_x000D_
4.6 Inova Diagnostics Inc_x000D_
4.6.1 Company Overview_x000D_
5 Recent Developments_x000D_
5.1 Corporate Communications_x000D_
5.1.1 Nov 17, 2025: Fortrea Appoints Agnieszka Gallagher as General Counsel_x000D_
5.1.2 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_
5.1.3 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager_x000D_
5.1.4 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
5.1.5 Oct 13, 2025: EASL CPGs Dissemination And Implementation Programme_x000D_
5.1.6 Oct 09, 2025: Abbott And Abbott Fund Support Northern Illinois Food Bank With $250,000 Grant To Address Childhood Hunger_x000D_
5.2 Financial Announcements_x000D_
5.2.1 Jan 05, 2026: Abbott Hosts Conference Call for Fourth-Quarter Earnings_x000D_
5.3 Government and Public Interest_x000D_
5.3.1 Nov 25, 2025: Fortrea to Present at Citi and Evercore Healthcare Conferences_x000D_
5.4 Other Significant Developments_x000D_
5.4.1 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
5.5 Product News_x000D_
5.5.1 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV_x000D_
5.5.2 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_
5.5.3 Jul 16, 2025: Multicenter Trial Confirms Near-Infrared Autofluorescence Increases Detection of Parathyroid Glands_x000D_
5.6 Strategy And Business Planning_x000D_
5.6.1 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_
5.6.2 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics_x000D_
5.6.3 Oct 29, 2025: EazeBio And UC Santa Cruz Form Strategic Partnership For Instrument-Free Diagnostics_x000D_
6 Appendix_x000D_
6.1 Research Methodology_x000D_
6.1.1 Coverage_x000D_
6.1.2 Secondary Research_x000D_
6.1.3 Primary Research_x000D_
6.1.4 Market Modeling and Forecasting_x000D_
6.1.5 Company Share Analysis_x000D_
6.1.6 Benchmarking_x000D_
6.2 GlobalData Consulting_x000D_
6.3 Contact Us_x000D_
6.4 Disclaimer